Science gets personal: Cell and gene therapy offer promise, but manufacturing challenges require solutions

Cell and gene therapy is at the forefront of personalized medicine, offering game-changing treatments for some of the most challenging diseases. But while the science is groundbreaking, the process of manufacturing these therapies is falling behind, limiting access for millions of patients.In this episode, we break down:Why cell and gene therapy is so hard to scale—and the impact of patient-specific treatments.How manufacturing constraints are slowing down access to life-saving therapies.Why only 3-4% of eligible patients receive CAR-T cell therapy—and what’s being done to change that.Decentralized manufacturing hubs—how moving production closer to patients can improve access.Automation, AI, and closed-system manufacturing—how technology is shaping the future of cell therapy.Ethical and economic challenges—balancing innovation, business sustainability, and patient accessibility.Can automation, AI, and logistics innovations fix the bottleneck in cell and gene therapy? Join us for a deep dive into the challenges and solutions shaping the future of healthcare.Key Takeaways:✔️ Cell and gene therapy is revolutionizing medicine, but manufacturing challenges are slowing patient access.✔️ Automation and AI are helping make these therapies faster, safer, and more scalable.✔️ Decentralized manufacturing hubs could bring life-saving treatments closer to patients.✔️ The future of medicine will be a hybrid of AI, automation, and human expertise.✔️ Transparency, collaboration, and innovation are key to making these treatments widely accessible.Subscribe to our podcast for more insights into the future of healthcare innovation, personalized medicine, and biotech advancements. Visit The Future of Commerce for expert analysis on how AI and automation are reshaping industries beyond medicine. Share this episode with healthcare professionals, researchers, and biotech leaders who need to stay ahead of these transformative trends.